Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 20 | 2023 | 109 | 7.900 |
Why?
|
| Graft vs Host Disease | 11 | 2023 | 55 | 5.220 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2022 | 52 | 2.660 |
Why?
|
| Transplantation Conditioning | 8 | 2022 | 40 | 0.930 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2021 | 6 | 0.850 |
Why?
|
| Mycoses | 1 | 2023 | 20 | 0.840 |
Why?
|
| Bacterial Infections | 1 | 2023 | 54 | 0.820 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 7 | 0.800 |
Why?
|
| Hematologic Neoplasms | 2 | 2020 | 19 | 0.780 |
Why?
|
| Calcineurin Inhibitors | 4 | 2023 | 16 | 0.770 |
Why?
|
| Roseolovirus Infections | 1 | 2021 | 4 | 0.710 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 2 | 0.690 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 11 | 0.690 |
Why?
|
| Humans | 26 | 2023 | 27307 | 0.680 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 2 | 0.670 |
Why?
|
| Infliximab | 1 | 2020 | 17 | 0.670 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 3 | 0.650 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 35 | 0.630 |
Why?
|
| Neoplasms | 1 | 2022 | 242 | 0.620 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 193 | 0.620 |
Why?
|
| Retrospective Studies | 7 | 2023 | 3551 | 0.470 |
Why?
|
| Recurrence | 5 | 2023 | 309 | 0.460 |
Why?
|
| Cyclophosphamide | 2 | 2023 | 49 | 0.420 |
Why?
|
| Transplantation, Homologous | 6 | 2020 | 279 | 0.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 14 | 0.340 |
Why?
|
| Child, Preschool | 2 | 2023 | 624 | 0.330 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2022 | 34 | 0.320 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 8 | 0.320 |
Why?
|
| Middle Aged | 8 | 2022 | 9068 | 0.270 |
Why?
|
| Adult | 9 | 2022 | 7945 | 0.250 |
Why?
|
| Risk Factors | 4 | 2020 | 2335 | 0.250 |
Why?
|
| Disease-Free Survival | 2 | 2022 | 179 | 0.230 |
Why?
|
| Tacrolimus | 2 | 2021 | 15 | 0.220 |
Why?
|
| Aged | 7 | 2023 | 9120 | 0.220 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 22 | 0.210 |
Why?
|
| Scedosporium | 1 | 2023 | 4 | 0.210 |
Why?
|
| Tissue Donors | 1 | 2023 | 79 | 0.200 |
Why?
|
| Pyrroles | 1 | 2022 | 23 | 0.200 |
Why?
|
| Whole-Body Irradiation | 1 | 2022 | 10 | 0.200 |
Why?
|
| Vidarabine | 1 | 2022 | 9 | 0.190 |
Why?
|
| Young Adult | 5 | 2020 | 2032 | 0.190 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 44 | 0.190 |
Why?
|
| Male | 6 | 2022 | 14887 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2022 | 61 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 121 | 0.190 |
Why?
|
| Adolescent | 4 | 2020 | 2185 | 0.180 |
Why?
|
| Incidence | 1 | 2023 | 763 | 0.180 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2020 | 1 | 0.170 |
Why?
|
| Leukocyte Count | 1 | 2020 | 63 | 0.170 |
Why?
|
| Pain | 2 | 2021 | 416 | 0.170 |
Why?
|
| Calcineurin | 1 | 2020 | 9 | 0.170 |
Why?
|
| Prognosis | 2 | 2020 | 808 | 0.170 |
Why?
|
| Cell Count | 1 | 2020 | 81 | 0.170 |
Why?
|
| Pyrazines | 1 | 2019 | 12 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 47 | 0.160 |
Why?
|
| Aniline Compounds | 1 | 2019 | 35 | 0.160 |
Why?
|
| Acute Disease | 1 | 2020 | 180 | 0.160 |
Why?
|
| Drug Resistance | 1 | 2019 | 47 | 0.160 |
Why?
|
| Steroids | 1 | 2019 | 23 | 0.160 |
Why?
|
| Typhlitis | 1 | 2019 | 2 | 0.160 |
Why?
|
| Mucositis | 1 | 2019 | 5 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2019 | 46 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 88 | 0.150 |
Why?
|
| Liver Diseases | 1 | 2019 | 35 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 92 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 243 | 0.150 |
Why?
|
| Allografts | 1 | 2019 | 216 | 0.150 |
Why?
|
| Age Factors | 1 | 2020 | 779 | 0.140 |
Why?
|
| Female | 5 | 2023 | 15334 | 0.140 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 2 | 0.130 |
Why?
|
| Child | 1 | 2020 | 1269 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3540 | 0.110 |
Why?
|
| Chromosome Aberrations | 2 | 2021 | 17 | 0.090 |
Why?
|
| Remission Induction | 2 | 2022 | 90 | 0.070 |
Why?
|
| Survival Rate | 2 | 2018 | 344 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2017 | 261 | 0.060 |
Why?
|
| Toes | 1 | 2023 | 6 | 0.050 |
Why?
|
| Voriconazole | 1 | 2023 | 12 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2023 | 43 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2022 | 1903 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2022 | 5 | 0.050 |
Why?
|
| Siblings | 1 | 2022 | 14 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2020 | 2 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 218 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 12 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 44 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 75 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 4 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 350 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 331 | 0.030 |
Why?
|
| Probability | 1 | 2017 | 88 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 22 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 631 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 1792 | 0.030 |
Why?
|